Psoriasis drug shows promise for heart health in small study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

In order for an individual to participate, they must meet all of the inclusion and exclusion criteria as outlined below. Inclusion Criteria include the following: 1. Moderate-to-severe psoriasis 2. Ages 18-90 3. Body surface area (BSA) involvement ≥ 3% OR 5-point Physician Global Assessment (PGA) Score ≥ 3 OR Psoriasis Area and Severity Index (PASI) score ≥ 12 4. Patients who have failed biologic therapy, topical steroids, phototherapy, or other systemic therapies will be required to have a wash-out period, which will be calculated accordingly to the specific drug (Appendix 1) 5. Evidence of at least one cardiovascular risk factor which includes hsCRP ≥ 2 mg/L, DM, obesity (BMI\>25), hyperlipidemia, hypertension, family history of early coronary artery disease, or evidence of metabolic syndrome ---Metabolic syndrome defined as at least three of the following: glucose\>100mg/dl or taking hypoglycemic agent, HDL\<40mg/dl (men) or 50 mg/dl (women), triglycerides ≥150mg/dl, waist circumference \>40 in mean or \>35 in women, or blood pressure ≥130/85 or taking anti-hypertensive. 6. If the patient is on a statin therapy, they must be on a stable dose for at least 6 months prior to enrollment. Exclusion Criteria include the following: 1. Documented history of other systemic inflammatory diseases, including SLE and RA, which in the opinion of the investigator would be inappropriate for enrollment. 2. Prior history of untreated chronic infection (tuberculosis), severe fungal infection, or known HIV positive, chronic hepatitis B or C infection), prior history of active solid malignancy, myeloproliferative or lymphoproliferative disease within 5 years, excluding treated non-melanoma skin cancer 3. Renal insufficiency (CrCl \<40 ml/min) 4. NYHA class IV heart failure 5. Patients requiring chronic treatment with oral prednisone \>10mg/day, methotrexate, or other immunosuppressive agents. 6. Pregnancy and Breastfeeding